Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.
Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.
Donor generosity provides lasting support for physician leadership, innovation and patient care in Orange County
ORANGE, Calif., Aug. 13, 2025 /PRNewswire/ -- Today Providence St....
Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.
Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.
MONTCLAIR, Calif., Aug. 13, 2025 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with Dr. Laurie Woll's practice, with locations...
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”) which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offering. All of the shares of common stock (or pre-funded warrants in lieu thereof) are being offered by the Company. The completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. The Company intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.
JOHNS CREEK, Ga., Aug. 13, 2025 /PRNewswire/ -- A.D.A.M. Consumer Health (A.D.A.M.), part of the global Ebix Group, has successfully passed and maintained its...
MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm...
Class Actions Seeks to Represent Untold Number of Caregivers Who Appealed Denials from the VA's Program of Comprehensive Assistance for Family Caregivers
WASHINGTON, Aug. 12,...
Newly formed MSO to support orthopedic practices and ASCs with strategic growth, back-end operations and clinical autonomy
LATHAM, N.Y., Aug. 12, 2025 /PRNewswire/ -- Evolve Orthopedic...
Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty AllianceJoins with recent urology acquisitions to bolster The Specialty Alliance's leadership in...